Transforaminal lumbar interbody fusion (TLIF) has been recognized as an effective surgical treatment for patients with refractory low back pain due to a variety of degenerative lumbar spinal disorders, including degenerative disc diseases and spondylolisthesis [1]. Minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) using a tubular retractor and microscope was developed to reduce collateral soft tissue injury. Recently, unilateral biportal endoscopic transforaminal lumbar interbody fusion (UBE-ULIF) has been attempted for lumbar degenerative disease and instability. Endoscopic lumbar interbody fusion is no longer a surgical technique that needs to be proven but has become a common endoscopic surgical technique [2]. UBE-TLIF offers the benefits of an unrestricted working area and less soft tissue damage because of the percutaneous target approach. Compared to MIS-TLIF, UBE-TLIF has shown reduced early postoperative back discomfort, less intraoperative blood loss, quicker ambulation onset, and shorter hospital stays [3]. Furthermore, UBE-TLIF demonstrated fusion rates and clinical outcomes that were equivalent to those of MIS-TLIF [4].